Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren's syndrome

Ann Rheum Dis. 2018 Dec;77(12):1838-1840. doi: 10.1136/annrheumdis-2018-213036. Epub 2018 Jun 23.

Authors

Miao Miao¹, Zhenye Hao¹, Yingying Guo¹, Xiaoying Zhang², Shengxiao Zhang¹, Jing Luo², Xiangcong Zhao², Chen Zhang², Xiaoqing Liu¹, Xiaoyan Wu², Dan Xu¹, Jinfang Zhao³, Xuechun Lu⁴, Chong Gao⁵, Xiaofeng Li²

Affiliations

¹ The Second Hospital of Shanxi Medical University, Taiyuan, China.
² Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
³ Department of Medical Statistics, Shanxi Medical University, Taiyuan, China.
⁴ Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China.
⁵ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

PMID: 29936436
DOI: 10.1136/annrheumdis-2018-213036

No abstract available

Keywords: Interleukin; Th17 cell; primary sjögren’s syndrome; treg cell.

Publication types

Letter

MeSH terms

Adult
Female
Humans
Immunologic Factors / therapeutic use*
Interleukin-2 / therapeutic use*
Male
Middle Aged
Sjogren's Syndrome / blood
Sjogren's Syndrome / drug therapy*
Sjogren's Syndrome / immunology
T-Lymphocytes, Regulatory / drug effects*
T-Lymphocytes, Regulatory / immunology
Th17 Cells / drug effects*
Th17 Cells / immunology

Substances

Immunologic Factors
Interleukin-2